Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

This study has been terminated.
(Administratively terminated.)
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT00716560
First received: July 14, 2008
Last updated: August 18, 2010
Last verified: August 2010

July 14, 2008
August 18, 2010
May 2005
March 2009   (final data collection date for primary outcome measure)
Determine incidence of nausea when receiving Dartmouth regimen chemotherapy for metastatic melanoma [ Time Frame: Week of treatment ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00716560 on ClinicalTrials.gov Archive Site
Assess the impact of systemic chemotherapy with Dartmouth regimen on quality of life of patients [ Time Frame: week of treatment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.

Questionnaires are completed on week of chemotherapy treatment referred to as Dartmouth regimen.

Observational
Observational Model: Case-Only
Not Provided
Not Provided
Non-Probability Sample

University practice patients with metastatic melanoma

  • Metastatic Melanoma
  • Nausea
Not Provided
A
Metastatic melanoma treatment with Dartmouth regimen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
8
March 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • confirmed diagnosis metastatic melanoma
  • 18 years and older
  • undergoing chemotherapy with Dartmouth regimen
  • medically stable to receive chemotherapy per physical and clinical laboratory tests

Exclusion Criteria:

  • No medical conditions that interfere with assessment of nausea and vomiting during chemotherapy
  • No cognitive disorder that impairs symptom assessment
  • No other investigational agent
  • Inability to swallow medications for nausea and vomiting
  • No gastric outlet obstruction
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00716560
05C.202, 2004-101, 0402005015
No
Takami Sato, MD, Thomas Jefferson University
Thomas Jefferson University
Merck Sharp & Dohme Corp.
Principal Investigator: Takami Sato, M.D.,Ph.D. Thomas Jefferson University
Thomas Jefferson University
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP